Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neurofilament Light Chain and Levels of Fatigue are Reduced by Dimethyl Fumarate Independent of Inflammatory Neuroaxonal Damage
Multiple Sclerosis
P16 - Poster Session 16 (5:30 PM-6:30 PM)
9-007

To investigate fatigue in newly diagnosed treatment naïve relapsing remitting multiple sclerosis (RRMS) patients before and after treatment with dimethyl fumarate (DMF). To analyze levels of neurofilament light chain (NFL) and cytokines in blood and CSF and their association, before and after DMF treatment.
No studies have prospectively investigated changes in fatigue and the relationship between NFL and cytokines after treatment with DMF.
Patients were prospectively enrolled and treated with DMF for 12 months. CSF were collected at baseline (BL) (n=34), after 12 months (n=31); blood was collected at BL and 3, 6 and 12 months (n=185). Blood and CSF were obtained from healthy controls (HC) (n=14). NFL concentrations were measured by Single Molecular Array (SiMoA) and cytokines with electrochemiluminescence. Fatigue was evaluated with the Modified Fatigue Impact Scale (MFIS) at BL, 3, 6, 12 and 24 months.
Patients were on average fatigued (MFISBL: 31.2±20.4) at baseline. MFIS scores were significantly reduced after treatment with DMF at 3, 6, 12 and 24 months (7.85±12.20, p<0.01; 7.75±15.59, p<0.01; 8.40±15.55, p<0.001; 10.25±10.92, p=0.0001). Significant reduction was also seen in MFISCOGNITIVE, MFISPHYSICAL, MFISPSYCHOSOCIAL  at month 3 (p<0.01), 6 (p<0.01-0.05), 12 (p<0.01-0.05) and 24 (p<0.01-0.05) months. Although NFL levels were reduced in both the blood and CSF after treatment with DMF (p<0.0001, respectively), no correlation was found with MFIS. Levels of 5 proinflammatory cytokines (TNF-beta, IL-12/IL-23p40, IL-16, IP-10, TARC) were also reduced in the CSF (p<0.01 to p<0.001) after DMF therapy, but they did not correlate with MFIS or its subscales.

Fatigue levels measured by MFIS were significantly decreased by DMF after 3-months of treatment. DMF also reduced the levels of NFL and proinflammatory cytokines both in blood and CSF. However, the relationship between fatigue and inflammatory neuroaxonal damage in MS could not be demonstrated in this prospective study.
Authors/Disclosures
Tobias Sejbaek, MD, PhD (Esbjerg Hospital)
PRESENTER 		Prof. Sejbaek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, Merck, NeuroXpharm, Novartis, Roche, Sandoz and Sanofi. The institution of Prof. Sejbaek has received research support from Merck, Novartis, Roche and Sanofi.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Zsolt Illes, MD (TENSI KFT. PECS) No disclosure on file